Good news is hard to come by at Amgen. The company's slipped on Friday after the biotech giant announced that its fading anemia blockbuster Aranesp failed a late-stage study for breast cancer. Combined with chemotherapy, there was no indication that the combinatorial approach helped shrink tumor sizes in early-stage breast cancer victims. And in the long-term follow-up, researchers said that there were more deaths and tumor progression in the Aranesp group than in the control group. Amgen has been restructuring as it deals with a cutback in the use of anemia drugs.
- see this release
- check out the report on the trial